Drug Trial Radar · NCT07615426
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Mar 2, 2026
Primary completion
Jun 21, 2027
Study completion Dec 3, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- May 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.
Conditions
- Schizophrenia
Interventions
AticaprantDrug
Participants will receive aticaprant during the double blind (DB) treatment phase.
PlaceboDrug
Participants will receive placebo during the DB treatment phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Screen Pass RateTime frame: Up to 28 days
- Exploratory Assessment-Specific Completion RateTime frame: Up to 126 days
- Total Assessment Completion RateTime frame: Up to 126 days
- Study Completion RateTime frame: Up to 126 days
- Adverse Events (AEs) Including AEs of Special Interest (AESI)Time frame: Up to 126 days
- Number of Participants with Abnormalities in Vital SignsTime frame: Up to 126 days
- Number of Participants with Abnormalities in 12-lead Electrocardiogram (ECG)Time frame: Up to and including 85 days
- Number of Participants with Abnormalities in Laboratory ParametersTime frame: Up to and including 85 days
- Number of Participants Reporting Changes in Body WeightTime frame: Up to and including 85 days
- Number of Participants Reporting Changes in Body Mass Index (BMI)Time frame: Up to and including 85 days
- Suicidality Using the Columbia Suicide Severity Rating Scale (C-SSRS) Over TimeTime frame: Up to 126 days
- Extrapyramidal Symptoms (EPS) Assessment Using the Modified Simpson-Angus Scale (MSAS) Total ScoreTime frame: Up to and including 85 days
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
CNS Network
Garden Grove, California · Recruiting
Synexus Clinical Research US Inc
Atlanta, Georgia · Recruiting
Uptown Research Institute
Chicago, Illinois · Recruiting
Western Michigan University
Kalamazoo, Michigan · Completed
Neurobehavioral Research Inc
Cedarhurst, New York · Recruiting
Evolution Research Group
Staten Island, New York · Recruiting
Community Clinical Research, Inc.
Austin, Texas · Recruiting
Pillar Clinical Research, LLC
Richardson, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.